Liraglutide in an adolescent population with obesity: a randomized, double-blind, placebo-controlled 5-week trial to assess safety, tolerability, and pharmacokinetics of Liraglutide in adolescents aged 1217 years
62 BAs may reduce the incidence of liver and gastrointestinal inflammation by activating nuclear FXR and GPCR signaling
M.ZhangM.LiangN.LiC.et al (2021)
[DOI] [PMC free article] [PubMed] [Google Scholar] 193.Perrelli A., Fatehbasharzad P., Benedetti V., Ferraris C., Fontanella M., De Luca E., Moglianetti M., Battaglia L., Retta S.F
Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes
The medication also dramatically reduced inflammatory cytokines and chemokines in RSV-infected mice's bronchoalveolar lavage fluid while not enhancing viral replication in the lungs